...
首页> 外文期刊>Radiography >Percutaneous transluminal angioplasty (PTA) and venous stenting in hemodialysis patients with vascular access-related venous stenosis or occlusion
【24h】

Percutaneous transluminal angioplasty (PTA) and venous stenting in hemodialysis patients with vascular access-related venous stenosis or occlusion

机译:血管通路相关性静脉狭窄或闭塞的血液透析患者的经皮腔内血管成形术(PTA)和静脉支架置入

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To present our experience with PTA and venous stenting in hemodialysis patients with vascular access (VA) related venous stenosis or occlusion.We studied retrospectively 22 hemodialysis patients with VA-related venous stenosis or occlusions that were treated with PTA and subsequent stenting. The following lesions were detected by digital subtraction venography: occlusion of the brachiocephalic and/or subclavian veins in four patients, stenosis (80–90%) of the same veins in 10 patients, stenosis (80–95%) of the axillary vein in four patients, brachial vein stenosis in two patients, and cephalic vein stenosis in two patients. The follow-up period ranged from 3 to 29 months (mean 15.4±9.8 months). Primary and cumulative stent patency was recorded.Twenty-two primary venous PTA–stent implantation procedures were performed using 25 stents. The initial deployment of these 25 stents was technically successful, with complete opening (>80%) of the vein's lumen in all but one patient (95.4%). The patency of the vein immediately after the stenting procedure was greater than 90% in 13 patients, 80–90% in eight patients, and less than 40% in the case involving failure. Seventeen episodes of re-obstruction occurred in 13 patients (59%), and all were treated with the same PTA–stent procedures. At the end of the study period 47 stents had been placed in patients. The 3, 6, 12 and 24-month primary patency rates were 88.3%, 65.3%, 45.6% and 25.5%, respectively. Overall cumulative stent patency was 95.4% after 3 months, 79% after 6 months, 74% after 12 months, and 62.8% after 24 months.PTA with primary venous stenting is an effective method for the treatment of VA-related stenosis or occlusion. However, repeat and sometimes multiple interventions are usually needed for the treatment of re-stenosis or re-occlusion episodes.
机译:为了介绍我们在有血管通路(VA)相关静脉狭窄或闭塞的血液透析患者中​​使用PTA和静脉支架置入的经验,我们回顾性研究了22例接受VA相关静脉狭窄或闭塞的血液透析患者,并接受了PTA和随后的支架治疗。通过数字减影静脉造影术检测到以下病变:4例患者的头臂静脉和/或锁骨下静脉闭塞,10例患者的相同静脉狭窄(80–90%),腋窝静脉狭窄(80–95%) 4例,臂静脉狭窄2例,头静脉狭窄2例。随访时间为3到29个月(平均15.4±9.8个月)。记录主要和累积的支架通畅。使用25个支架进行了22个主要的PTA静脉置入支架。这25个支架的最初部署在技术上是成功的,除一名患者(95.4%)外,所有患者的静脉腔完全开放(> 80%)。支架置入术后立即的静脉通畅率在13例患者中大于90%,在8例患者中为80-90%,在涉及衰竭的情况下小于40%。 13例患者(59%)发生了17次再梗阻,所有患者均接受了相同的PTA支架手术。在研究期末,已在患者体内放置了47个支架。 3、6、12和24个月的主要通畅率分别为88.3%,65.3%,45.6%和25.5%。 3个月后的总体累积支架通畅率为95.4%,6个月后为79%,12个月后为74%,24个月后为62.8%。PTA与原位静脉支架置入术是治疗VA相关狭窄或闭塞的有效方法。然而,通常需要重复且有时需要多次干预以治疗再狭窄或再闭塞发作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号